Recent News

• 06.09.2025 - Ascendis Business Update
• 06.09.2025 - Ascendis Business Update
• 06.09.2025 - TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
• 06.09.2025 - TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
• 06.09.2025 - TransCon® hGH Boosted Treatment Benefits of TransCon® CNP in Children with Achondroplasia at Week 26 Interim Analysis of the Phase 2 COACH Trial
• 06.02.2025 - FDA Accepts TransCon® CNP NDA for Priority Review
• 06.02.2025 - FDA Accepts TransCon® CNP NDA for Priority Review
• 06.02.2025 - FDA Accepts TransCon® CNP NDA for Priority Review
• 05.13.2025 - New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)
• 05.13.2025 - New Data Shows Improvements in Growth and Bone Morphometry in Children with Achondroplasia Treated with TransCon® CNP (Navepegritide)

Recent Filings

• 06.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.09.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 06.09.2025 - EX-99.1 EX-99.1
• 06.02.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.28.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.14.2025 - SD Specialized disclosure report
• 05.14.2025 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 05.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.14.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors